Core Viewpoint - The company announced a significant expected net profit loss for the year 2025, indicating a worsening financial situation compared to 2024 [1] Financial Performance - The company anticipates a net profit loss attributable to shareholders ranging from 58 million to 75 million yuan for 2025, which is an increase in the loss margin compared to 2024 [1] - In Q3 2025, the company reported a single-quarter net profit loss of 21.28 million yuan, representing a year-on-year decline of 135.33% [1] Market Performance - Over the past week (February 9 to 12, 2026), the company's stock price has shown a downward trend, with a decline of 0.56% and a fluctuation range of 3.39% [2] - On February 12, the closing price was 21.42 yuan, down 0.97% for the day, with a trading volume of 22.56 million yuan [2] - The stock has seen a net inflow of 376,000 yuan on that day, but a cumulative net inflow of 3.32 million yuan over the past five days, indicating short-term capital speculation [2] Industry Context - On February 12, 2026, the company’s announcements regarding fund flows and expected losses drew significant attention, with the overall pharmaceutical and biotechnology sector declining by 0.60%, indicating the company's performance was slightly weaker than the industry average [3]
共同药业2025年业绩预亏，股价震荡下行